Literature DB >> 12720236

Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?

Daniel Soffer1, Issam Moussa, Kishore J Harjai, Judith A Boura, Simon R Dixon, Cindy L Grines, William W O'Neill, Gary S Roubin, Jeffrey W Moses.   

Abstract

Pretreatment with thienopyridines has been shown to improve clinical outcomes in patients undergoing percutaneous coronary intervention (PCI). We determine the impact of angina class on inhibition of platelet aggregation (IPA) following clopidogrel loading. Seventy-two patients (mean age, 64 +/- 11 years; 76% male) were pretreated with 450 mg of clopidogrel at least 3 hr prior to PCI. All patients received ASA 325 mg prior to the procedure. Patients were classified into two groups according to angina class: group 1 = stable angina or Braunwald class 1 unstable angina (UA; n = 33); group 2 = Braunwald class 2 or 3 UA (n = 39). IPA was measured prior to PCI, with the Ichor point-of-care platelet analyzer (Helena Laboratories, Beaumont, TX), using 20 microM of ADP. Group 2 patients were more likely to have prior MI (54% vs. 27%; P = 0.023), prior CABG (33% vs. 5%; P = 0.046), and received IV heparin (64% vs. 27%; P = 0.0018). Mean IPA was significantly lower in group 2 compared to group 1 (19% +/- 22% vs. 32% +/- 22%; P = 0.004). In multivariate analysis, higher angina class was independently associated with lower IPA (P = 0.018). Patients with UA undergoing PCI have a lower IPA following clopidogrel loading with 450 mg. This may indicate the possibility of clopidogrel resistance in such patients. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720236     DOI: 10.1002/ccd.10494

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  14 in total

1.  [Primary prevention of coronary heart disease with aspirin].

Authors:  W Kübler; H Darius
Journal:  Z Kardiol       Date:  2005

Review 2.  Contemporary issues on clopidogrel therapy.

Authors:  Giuseppe Patti; Germano Di Sciascio
Journal:  Intern Emerg Med       Date:  2009-01-08       Impact factor: 3.397

Review 3.  Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter?

Authors:  Wai-Hong Chen
Journal:  Curr Cardiol Rep       Date:  2006-07       Impact factor: 2.931

4.  Clinical importance of aspirin and clopidogrel resistance.

Authors:  Gergely Feher; Andrea Feher; Gabriella Pusch; Katalin Koltai; Antal Tibold; Beata Gasztonyi; Elod Papp; Laszlo Szapary; Gabor Kesmarky; Kalman Toth
Journal:  World J Cardiol       Date:  2010-07-26

Review 5.  Antiplatelet therapy for atherothrombotic disease: how can we improve the outcomes?

Authors:  Martin Moser; Christoph Bode
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

6.  Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.

Authors:  S Prabhakaran; K R Wells; V H Lee; C A Flaherty; D K Lopes
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

7.  Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?

Authors:  K Ibrahim; N Hass; S Kolschmann; R H Strasser; R C Braun-Dullaeus
Journal:  Clin Res Cardiol       Date:  2008-07-28       Impact factor: 5.460

8.  Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.

Authors:  José Luis Ferreiro; José Carlos Sánchez-Salado; Montserrat Gracida; Ana Lucrecia Marcano; Gerard Roura; Albert Ariza; Josep Gómez-Lara; Victoria Lorente; Rafael Romaguera; Sílvia Homs; Guillermo Sánchez-Elvira; Luis Teruel; Kristian Rivera; Silvia Gabriela Sosa; Joan Antoni Gómez-Hospital; Dominick J Angiolillo; Angel Cequier
Journal:  J Cardiovasc Transl Res       Date:  2013-12-21       Impact factor: 4.132

9.  Complete lysis of left ventricular giant thrombus with fibrinolytic therapy in clopidogrel resistant patient.

Authors:  Vedat Davutoglu; Serdar Soydinc; Yusuf Sezen
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

Review 10.  Investigating the mechanisms of hyporesponse to antiplatelet approaches.

Authors:  Eugene Braunwald; Dominick Angiolillo; Eric Bates; Peter B Berger; Deepak Bhatt; Christopher P Cannon; Mark I Furman; Paul Gurbel; Alan D Michelson; Eric Peterson; Stephen Wiviott
Journal:  Clin Cardiol       Date:  2008-03       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.